德国拜耳利伐沙班的使用说明

Rivaroxaban is the world's first oral direct factor Xa inhibitor, mainly used to treat venous thrombosis in adults. Compared with traditional anticoagulants, Rivaroxaban has accurate efficacy, does not require constant monitoring, has good safety and is easy to use. It is expected to become an alternative drug to heparin and vitamin K antagonists.

At present, Rivaroxaban has been approved in more than 100 countries around the world and has been successfully marketed by Bayer in more than 75 countries. In June 2009, Rivaroxaban was officially launched in China and is used to prevent or reduce the formation of blood clots, deep vein thrombosis (DVT) and pulmonary embolism (PE) after hip or knee replacement surgery.

Bayer is headquartered in Leverkusen, Germany. Polymers, pharmaceuticals and health care, chemicals and agriculture are the company's four pillar industries. The company's product categories exceed 10,000 types. The company has produced aspirin, heroin, Rivaroxaban and other products.

Instructions for use of Rivaroxaban from Bayer in Germany: The initial recommended dose of Rivaroxaban for the treatment of acute venous thrombosis (DVT) is 15 mg twice a day for the first three weeks, and then the dose of Rivaroxaban for maintenance treatment and reducing the risk of recurrent PE of venous thrombosis (DVT) is 20 mg once a day. Patients should note: Rivaroxaban 10 mg can be taken with food or alone. Rivaroxaban 15 mg or 20 mg tablets should be taken with food.

The above is the introduction about Rivaroxaban. If patients have other questions about Rivaroxaban (such as drug prices, purchase channels, etc.), they can consult the medical companion travel service.

Recommended related hot articles: /newsDetail/89992.html